IL176071A0 - Nicotinic acetylcholine receptor ligands - Google Patents

Nicotinic acetylcholine receptor ligands

Info

Publication number
IL176071A0
IL176071A0 IL176071A IL17607106A IL176071A0 IL 176071 A0 IL176071 A0 IL 176071A0 IL 176071 A IL176071 A IL 176071A IL 17607106 A IL17607106 A IL 17607106A IL 176071 A0 IL176071 A0 IL 176071A0
Authority
IL
Israel
Prior art keywords
acetylcholine receptor
receptor ligands
nicotinic acetylcholine
nicotinic
ligands
Prior art date
Application number
IL176071A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Phillips Eifion
Jacobs Robert
Ernst Glen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Phillips Eifion, Jacobs Robert, Ernst Glen filed Critical Astrazeneca Ab
Publication of IL176071A0 publication Critical patent/IL176071A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL176071A 2003-12-22 2006-05-31 Nicotinic acetylcholine receptor ligands IL176071A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53171203P 2003-12-22 2003-12-22
PCT/SE2004/001940 WO2005061494A1 (en) 2003-12-22 2004-12-20 Nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
IL176071A0 true IL176071A0 (en) 2006-10-05

Family

ID=34710246

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176071A IL176071A0 (en) 2003-12-22 2006-05-31 Nicotinic acetylcholine receptor ligands

Country Status (14)

Country Link
US (1) US20070270458A1 (cg-RX-API-DMAC7.html)
EP (1) EP1699786A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007515478A (cg-RX-API-DMAC7.html)
KR (1) KR20060125812A (cg-RX-API-DMAC7.html)
CN (1) CN1914201A (cg-RX-API-DMAC7.html)
AU (1) AU2004303737A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417927A (cg-RX-API-DMAC7.html)
CA (1) CA2550844A1 (cg-RX-API-DMAC7.html)
IL (1) IL176071A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06007026A (cg-RX-API-DMAC7.html)
NO (1) NO20063356L (cg-RX-API-DMAC7.html)
SG (1) SG149052A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005061494A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605074B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2582339C2 (ru) 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
EP2593447B1 (de) 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
CA3169697A1 (en) * 2020-02-28 2021-09-02 Dominic Reynolds Thiophenyl derivatives useful for modulating nucleic acid splicing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529548A1 (fr) * 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
EP0287196B1 (en) * 1987-02-18 1994-11-23 Beecham Group Plc Indole derivatives, process for their preparation and pharmaceutical compositions containing them
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2002015662A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
JP2004506734A (ja) * 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
DE10156719A1 (de) * 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide

Also Published As

Publication number Publication date
ZA200605074B (en) 2007-05-30
SG149052A1 (en) 2009-01-29
WO2005061494A1 (en) 2005-07-07
US20070270458A1 (en) 2007-11-22
MXPA06007026A (es) 2006-08-31
KR20060125812A (ko) 2006-12-06
CA2550844A1 (en) 2005-07-07
AU2004303737A1 (en) 2005-07-07
BRPI0417927A (pt) 2007-04-17
EP1699786A1 (en) 2006-09-13
NO20063356L (no) 2006-09-21
JP2007515478A (ja) 2007-06-14
CN1914201A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
IL183603A0 (en) Nicotinic acetylcholine receptor ligands
EP1687004A4 (en) PYRIDINE COMPOUNDS
HUS000495I2 (hu) Necitumumab
IL195019A0 (en) Nicotinic acetylcholine receptor ligands 101
PL376702A1 (pl) Ligandy receptorów melanokortyny
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
IL175993A0 (en) Nicotinic acetylcholine receptor ligands
IL164766A0 (en) Melanocortin receptor ligands
EP1689612A4 (en) ROLLER MECHANISM HOUSING
IL183598A0 (en) Nicotinic acetylcholine receptor ligands
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
IL176073A0 (en) Nicotinic acetylcholine receptor ligands
ZA200705042B (en) Nicotinic acetylcholine receptor ligands
IL173337A0 (en) Receptor
GB0414998D0 (en) Monodonor ligands
HK1096666A (en) Nicotinic acetylcholine receptor ligands
HK1096667A (en) Nicotinic acetylcholine receptor ligands
HK1095323A (en) Nicotinic acetylcholine receptor ligands
ZA200809396B (en) Nicotinic acetylcholine receptor ligands 101
IL174218A0 (en) Ligands
GB0313709D0 (en) Ligands
HK1107989A (en) Nicotinic acetylcholine receptor ligands
GB0418583D0 (en) Windbreaks
GB0325206D0 (en) Mat
AU2002304849A1 (en) Nicotinic acetylcholine receptor ligands